Picture of Anixa Biosciences logo

ANIX Anixa Biosciences Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

Annual cashflow statement for Anixa Biosciences, fiscal year end - October 31st, USD millions except per share, conversion factor applied.

2019
October 31st
2020
October 31st
2021
October 31st
2022
October 31st
2023
October 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-11.8-10.1-13.1-13.8-9.93
Depreciation
Amortisation
Non-Cash Items6.134.348.116.794.78
Unusual Items
Other Non-Cash Items
Changes in Working Capital0.478-0.4590.0790.485-1.06
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Cash from Operating Activities-4.74-6.18-4.94-6.49-6.21
Capital Expenditures-0.175-0.0160
Purchase of Fixed Assets
Other Investing Cash Flow Items-0.35-0.29-3.92-10.7-5.6
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-0.525-0.306-3.92-10.7-5.6
Financing Cash Flow Items0.014
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities5.79.4131.60.4520.366
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash0.4362.9322.7-16.8-11.4